Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS

Investigational New Drugs

Volumn 15, Issue 3, 1997, Pages 195-206

  Chan, Kenneth K ^a   Bakhtiar, Ray ^a,b   Jiang, Chun ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Depsipeptide; Electrospray LC MS MS; Oral absorption; Pharmacokinetics

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; DEPSIPEPTIDE; FR 901228; MACROGOL 400; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHROMOBACTERIUM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STANDARD; TUMOR CELL LINE; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPSIPEPTIDES; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; PEPTIDES, CYCLIC; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS;

EID: 0030667857     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005847703624     Document Type: Article

References (18)

1. Ueda H, Nakajim H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacteriun violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and bio logical properties, and antitumor activity. J Antibiotics 47: 301-310, 1994.
2. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M: Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacteriun violaceum No. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotech Biochem 58(9): 1579-1583, 1994.
3. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Shimomura K: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiotics 47: 315-323, 1994.
4. Page JG, Rodman LE, Heath JE, Tomaszewski JE, Smith AC: Effect of infusion rat on the toxicity of depsipeptide (NSC-630176) in beagle dogs. Proc Am Assoc Cancer Res 36: 368, 1995.
5. Hong PS, Chan KK: Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrome try. Biomed Mass Spectrom 14: 167-172, 1987.
6. Gibaldi M, Perrier D: Pharmacokinetics. 2nd ed, Marcel-Dekker, New York, 1982.
7. Fouda H, Nocerini M, Schneider R, Gedutis C: Quantitative analysis by high performance liquid chromatography atmospheric pressure chemical ionization mass spectrometry: the determination of the renin inhibitor CP-80, 794 in human serum. J Am Soc Mass Spectrom 2: 164-167, 1991.
8. Gilbert JD, Hand EL, Yuan AS, Olah TV, Covey TR: Determination of L-365, 260, a new cholecytokinin receptor (CCK-B) antagonist, in plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Biol Mass Spectrom 21: 63-68, 1992.
9. Kaye B, Clark MWH, Cussans NJ, Macrae PV, Stopher DA: The sensitive determination of abanoquid in blood by highperformance liquid chromatograph/atmospheric pressure ionization mass spectrometry. Biol Mass Spectrom 21: 585-589, 1992.
10. Lee HJ: Biopharmaceutical properties and pharmacokinetics of peptide and protein drugs. In Taylor MD and Amidon GL (eds) Peptide-Based Drug Design. Am Chem Soc, Washington, DC, 1995, pp 69-147.
11. Lee VHL, Dodda-Kashi S, Grass GM, Rubas W: Oral route of peptide and protein drug delivery. In Lee VHL (ed) Peptide and Protein Drug Delivery. Marcel-Dekker, New York, 1991, pp 691-718.
12. Hu M and Amidon G: Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci 77(12): 1007-1011, 1988.
13. Friedman DI, Amidon GL: Passive and carrier-mediated intestinal absorption components of two antiotensin converting enzyme (ACE) inhibitor produgs in rats: enalapril and fosinopril. Pharm Res 6(12): 1043-1047, 1989.
14. Yee S and Amidon GL: Oral absorption of antiotensin-converting enzyme inhibitors and peptide prodrugs. In Tayor MD and Amidon GL (eds) Peptide-Based Drug Design. Am Chem Soc, Washington, DC, 1995, pp 135-136.
15. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR: The effect of food on cyclosporin absorption. Transplantation 40: 174-176, 1985.
16. Ptachcinski RJ, Venkataramanan R, Burckart GJ: Clinical pharmacokinetics of cyclosporin. Clin Pharmacokin 11(2): 107-132, 1986.
17. Murata K, Noda K, Kohno K, Samejima M: Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models. J Pharm Sci 76: 109-113.
18. Suttle AB, Pollack GM, Brouwer KLR (1992): Use of pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm Res 9: 350-356, 1987.